Vale Biolabs
Vale Biolabs provides time-resolved, multimodal datasets from living human brain organoids to help pharmaceutical and biotech companies understand how drugs affect brain tissue across development, ageing, and disease. The company runs standardized studies on its organoids and delivers full experimental documentation alongside analysis-ready outputs. Its platform integrates imaging, functional activity, and molecular readouts into a single, documented dataset.
- Drug Discovery & Therapeutics
- Biotechnology
- Data & Analytics
Funding
Raised to date
€164KRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Est. $178.8KFounders
Founder details are not available yet.
Product
Problem
Drug development for central nervous system (CNS) conditions is hampered by the limited translatability of animal models and static in vitro assays, which fail to capture how living human brain tissue responds to compounds over time. This gap leads to late-stage clinical failures and slows the delivery of new therapies for neurological and psychiatric diseases.
Solution
Vale Biolabs measures how living human brain tissue changes over time—across development, ageing, and disease—and how drugs alter those changes. The company grows brain organoids under standardized conditions and runs studies designed around a client's specific drug program. Each study produces a time-resolved, multimodal dataset that combines imaging, functional activity, and molecular readouts, documented from protocol to output. Clients receive the full dataset, experimental documentation, and analysis-ready outputs, enabling them to assess drug effects on human brain tissue without needing to build organoid capabilities in-house.
Target Audience
Primary customers are pharmaceutical and biotechnology companies running CNS drug development programs that need human-relevant efficacy and safety data from living brain tissue models.
Features
- Time-resolved longitudinal measurements of living human brain organoids capturing changes across development, ageing, and disease states
- Multimodal data integration combining imaging, functional activity, and molecular readouts in a single dataset
- Standardized organoid culture conditions and study protocols designed for reproducibility across programs
- Full experimental documentation from protocol to output, supporting regulatory and publication-grade evidence
- Analysis-ready outputs delivered to clients for direct use in drug development decision-making
- Study design tailored to each client's CNS program, with services available now and expanded capabilities planned from 2027